BENEVOLENTAI
Important note: Odyssey Acquisition S.A. will be renamed BenevolentAI following completion of the Business Combination and approval of the Prospectus, both scheduled for 22 April 2022. BenevolentAI’s securities will be admitted to Euronext Amsterdam on 25 April 2022. The final number of BenevolentAI securities to be admitted on Euronext Amsterdam will be provided on 22 April 2022, following approval of the Prospectus. Upon admisison of BenevolentAI’s securities on 25 April, this IPO Showcase page will be amended to reflect BenevolentAI’s information.
Identification
Listing sponsor / Euronext Growth Advisor
ABN AMRO BANK N.V.
Ticker
BAI
Codice ISIN
LU2355630455
codice LEI
2221003P54KEDC3P4Z33
Mercato
Euronext
Borsa
Amsterdam
Comparto
Compartment A
ICB
20103010 Biotechnology
Indirizzo web
https://www.benevolent.com
Operation
Data IPO
Lun 25/04/2022
Tipologia IPO
SPAC – Business combination
Descrizione dell'operazione
The final number of securities to be admitted to Euronext Amsterdam will be provided upon publication of the approved prospectus on 22 April, 2022
Profilo società
BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.
The Company’s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.
Fonte:
Cofisem
-
Ultimo aggiornamento:
07 Feb 2025
Dirigenti principali
| Chairwomen and Chief Executive Officer | Kenneth Mulvany | ||||
| Chief Financial Officer | Michael Brennan | ||||
| Strategy Director | Michael Brennan | ||||
| Chief Human Resources Officer | Anna Fullerton-Batten | ||||
| Chief Business Officer | Ivan Griffin | ||||
| Company Secretary | Will Scrimshaw | ||||
| Head of Investor Relations | Fleur Wood | ||||
| Fonte: Cofisem - Ultimo aggiornamento: 07 Feb 2025 | |||||
Dati principali
| Millenium | 2023 | 2022 | 2021 | ||
|---|---|---|---|---|---|
| Income from portfolio management | 0 | 0 | 0 | ||
| Cash management income | 0 | 0 | 0 | ||
| Net sales | 7.331 | 10.560 | 4.625 | ||
| Income from real estate investment | |||||
| Other income from the activity | 0 | ||||
| Income from ordinary activities | 7.331 | 10.560 | 4.625 | ||
| Operating income | -77.573 | -197.034 | -121.322 | ||
| Cost of financial indebtedness net | -3.528 | -1.127 | 487 | ||
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | -63.317 | -163.928 | -107.655 | ||
| Net income (Group share) | -63.317 | -163.928 | -107.655 | ||
| Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | ||
| Length of fiscal year (month) | 12 | 12 | 7 | ||
| Currency & Unit | GBP - thousands | GBP - thousands | GBP - thousands | ||
| Account Standards | IFRS | IFRS | IFRS | ||
| Fonte: Cofisem - Ultimo aggiornamento: 07 Feb 2025 | |||||